Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma (MAGNETISMM17)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05462639 |
|
Expanded Access Status :
Available
First Posted : July 18, 2022
Last Update Posted : September 11, 2023
|
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
Elranatamab is a bispecific antibody: binding of elranatamab to CD3- expressing T-cell and BCMA- expressing multiple myeloma cells causes targeted T-cell mediated cytotoxicity.
This expanded access protocol will provide access to elranatamab until it becomes commercially available to patients who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 antibody and have no access to other comparable/alternative therapy and for whom elranatamab could be a possible treatment option.
| Condition or disease | Intervention/treatment |
|---|---|
| Multiple Myeloma | Drug: Elranatamab (PF-06863135) |
Study C1071017 is a single-arm, open-label study in patient with relapsed /refractory multiple myeloma.
Each patient will receive study intervention until disease progression, unacceptable toxicity, withdrawal of consent, study termination or until elranatamab becomes commercially available.
| Study Type : | Expanded Access |
| Expanded Access Type : | Treatment IND/Protocol |
| Official Title: | ELRANATAMAB (PF-06863135) MONOTHERAPY EXPANDED ACCESS PROTOCOL FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY AND HAVE NO ACCESS TO OTHER COMPARABLE/ALTERNATIVE THERAPY |
- Drug: Elranatamab (PF-06863135)
BCMA-CD3 bispecific antibody
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Prior diagnosis of MM as defined according to IMWG criteria .
- Patients who are ineligible for participation in any ongoing clinical trial of elranatamab, including lack of access due to geographical limitations, and who have exhausted all other treatment options or experience lack of access to commercially available therapies due to geographical, financial or socioeconomic limitations.
- Measurable disease at screening based on IMWG criteria as defined by at least 1 of the following:
- Serum M-protein ≥0.5 g/dL (≥5 g/L)
- Urinary M-protein excretion ≥200 mg/24 hours
- Involved FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65).
- Refractory to at least one IMiD, one PI, and one anti-CD38 antibody.
- Relapsed/refractory to last anti-MM regimen.
- ECOG performance status 0-1.
- Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1.
- Not pregnant, willing to use contraception
Exclusion Criteria:
- Smoldering MM; plasma cell leukemia; POEMS syndrome; Waldenström's macroglobulinemia; amyloidosis; stem cell transplant within 12 weeks prior to enrollment or active GVHD
- Previous treatment with BCMA directed therapy;
- Active HBV, HCV, SARS- CoV-2, HIV or any active, uncontrolled bacterial, fungal, or viral infection.
Active infections must be resolved at least 14 days prior to enrollment.
- Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ or Stage 0/1 with minimal risk of recurrence per treating physician.
- Previous administration with an investigational drug or vaccine within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05462639
| Contact: Pfizer CT.gov Call Center | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
Show 35 study locations
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
| Responsible Party: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT05462639 |
| Other Study ID Numbers: |
C1071017 |
| First Posted: | July 18, 2022 Key Record Dates |
| Last Update Posted: | September 11, 2023 |
| Last Verified: | September 2023 |
|
Multiple Myeloma Erlanatamab Expanded Access MM17 MagnetisMM-17 BCMA BCMA antibody |
Advanced multiple myeloma Relapse/Refractory RRMM MagnetisMM MagnetisMM US Bispecific Antibody |
|
Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases |
Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases |